Daniil Gataulin
Stock Analyst at Chardan Capital
(4.74)
# 186
Out of 5,182 analysts
134
Total ratings
60.16%
Success rate
38.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daniil Gataulin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGTX Cognition Therapeutics | Maintains: Buy | $4 | $1.28 | +212.50% | 9 | Mar 27, 2026 | |
| MGTX MeiraGTx Holdings | Maintains: Buy | $35 | $9.13 | +283.35% | 8 | Mar 27, 2026 | |
| OCGN Ocugen | Maintains: Buy | $7 | $1.70 | +311.76% | 17 | Mar 25, 2026 | |
| ZURA Zura Bio | Maintains: Buy | $10 → $11 | $5.41 | +103.33% | 4 | Mar 23, 2026 | |
| ANNX Annexon | Maintains: Buy | $16 | $6.10 | +162.30% | 2 | Mar 20, 2026 | |
| CRVO CervoMed | Maintains: Buy | $15 → $21 | $3.82 | +449.74% | 9 | Mar 18, 2026 | |
| IRD Opus Genetics | Maintains: Buy | $9 → $11 | $5.12 | +114.84% | 4 | Mar 12, 2026 | |
| QURE uniQure | Maintains: Buy | $16 → $31 | $17.90 | +73.18% | 13 | Mar 9, 2026 | |
| EYPT EyePoint | Maintains: Buy | $27 → $29 | $13.60 | +113.24% | 13 | Mar 4, 2026 | |
| OTLK Outlook Therapeutics | Maintains: Neutral | $1 | $0.29 | +250.88% | 12 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 | $9.52 | +120.59% | 5 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $50 | $8.62 | +480.05% | 16 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $6.02 | +215.61% | 1 | Dec 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $61 | $26.74 | +128.12% | 7 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 | $44.11 | -68.26% | 4 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 | $27.11 | +88.12% | 9 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $2,200 | $4.59 | +47,830.28% | 1 | Mar 7, 2024 |
Cognition Therapeutics
Mar 27, 2026
Maintains: Buy
Price Target: $4
Current: $1.28
Upside: +212.50%
MeiraGTx Holdings
Mar 27, 2026
Maintains: Buy
Price Target: $35
Current: $9.13
Upside: +283.35%
Ocugen
Mar 25, 2026
Maintains: Buy
Price Target: $7
Current: $1.70
Upside: +311.76%
Zura Bio
Mar 23, 2026
Maintains: Buy
Price Target: $10 → $11
Current: $5.41
Upside: +103.33%
Annexon
Mar 20, 2026
Maintains: Buy
Price Target: $16
Current: $6.10
Upside: +162.30%
CervoMed
Mar 18, 2026
Maintains: Buy
Price Target: $15 → $21
Current: $3.82
Upside: +449.74%
Opus Genetics
Mar 12, 2026
Maintains: Buy
Price Target: $9 → $11
Current: $5.12
Upside: +114.84%
uniQure
Mar 9, 2026
Maintains: Buy
Price Target: $16 → $31
Current: $17.90
Upside: +73.18%
EyePoint
Mar 4, 2026
Maintains: Buy
Price Target: $27 → $29
Current: $13.60
Upside: +113.24%
Outlook Therapeutics
Feb 18, 2026
Maintains: Neutral
Price Target: $1
Current: $0.29
Upside: +250.88%
Feb 18, 2026
Maintains: Buy
Price Target: $21
Current: $9.52
Upside: +120.59%
Feb 10, 2026
Maintains: Buy
Price Target: $52 → $50
Current: $8.62
Upside: +480.05%
Dec 23, 2025
Initiates: Buy
Price Target: $19
Current: $6.02
Upside: +215.61%
Nov 17, 2025
Maintains: Buy
Price Target: $61
Current: $26.74
Upside: +128.12%
Nov 17, 2025
Maintains: Neutral
Price Target: $14
Current: $44.11
Upside: -68.26%
Nov 11, 2025
Maintains: Buy
Price Target: $51
Current: $27.11
Upside: +88.12%
Mar 7, 2024
Maintains: Buy
Price Target: $2,200
Current: $4.59
Upside: +47,830.28%